Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 5/20 | 0.40 |
| ▸ | PLK1 | P53350 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5129060 | 0.86 | DYRK1A (0.42) | DYRK1ACNR2BRD4PLK1TDP1 | |
| SCHEMBL4241099 | 0.80 | CNR2 (0.44) | DYRK1ACNR2BRD4PLK1TDP1 | |
| SCHEMBL5129516 | 0.76 | CNR2 (0.41) | DYRK1ACNR2BRD4TDP1STING1 | |
| SCHEMBL4511556 | 0.75 | CNR2 (0.44) | DYRK1ACNR2BRD4PLK1TDP1 | |
| SCHEMBL6519106 | 0.73 | CHEK1 (0.52) | DYRK1ACNR2BRD4PLK1PIM1 | |
| SCHEMBL6508615 | 0.72 | DYRK1A (0.53) | DYRK1ACNR2BRD4PLK1 | |
| SCHEMBL6511693 | 0.72 | PIM1 (0.49) | DYRK1ACNR2BRD4PLK1TDP1 | |
| SCHEMBL4004504 | 0.72 | CHEK1 (0.50) | — | |
| SCHEMBL4023100 | 0.71 | CHEK1 (0.33) | DYRK1A | |
| SCHEMBL4017813 | 0.71 | CHEK1 (0.33) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485649-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7485649-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080214594-A1 | Inhibitors Of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-09-04 | — | — | US | disclosed |
| US-20080214594-A1 | Inhibitors Of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2008-09-04 | — | — | US | disclosed |
| EP-1836807-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006074207-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214594-A1 | Inhibitors Of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | DYRK1A 734/4885CNR2 4051/4885BRD4 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.